Dr. Oh on the Management of Hormone-Sensitive Prostate Cancer

William Oh, MD
Published: Wednesday, Nov 15, 2017



William Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.

One of the biggest developments for the treatment of patients with advanced prostate cancer has been the management of metastatic hormone-sensitive prostate cancer, says Oh. The CHAARTED trial compared androgen deprivation therapy (ADT) versus ADT plus 6 cycles of docetaxel. This study favored the early use of chemotherapy, while the STAMPEDE trial further confirmed those findings.

The LATITUDE trial investigated ADT plus or minus abiraterone (Zytiga) and showed a comparable benefit of up to 2 to 3 years of abiraterone plus prednisone in the treatment of hormone-sensitive prostate cancer.
 


William Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.

One of the biggest developments for the treatment of patients with advanced prostate cancer has been the management of metastatic hormone-sensitive prostate cancer, says Oh. The CHAARTED trial compared androgen deprivation therapy (ADT) versus ADT plus 6 cycles of docetaxel. This study favored the early use of chemotherapy, while the STAMPEDE trial further confirmed those findings.

The LATITUDE trial investigated ADT plus or minus abiraterone (Zytiga) and showed a comparable benefit of up to 2 to 3 years of abiraterone plus prednisone in the treatment of hormone-sensitive prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x